Nature Communications (Mar 2023)
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
- Aleix Prat,
- Fara Brasó-Maristany,
- Olga Martínez-Sáez,
- Esther Sanfeliu,
- Youli Xia,
- Meritxell Bellet,
- Patricia Galván,
- Débora Martínez,
- Tomás Pascual,
- Mercedes Marín-Aguilera,
- Anna Rodríguez,
- Nuria Chic,
- Barbara Adamo,
- Laia Paré,
- Maria Vidal,
- Mireia Margelí,
- Ester Ballana,
- Marina Gómez-Rey,
- Mafalda Oliveira,
- Eudald Felip,
- Judit Matito,
- Rodrigo Sánchez-Bayona,
- Anna Suñol,
- Cristina Saura,
- Eva Ciruelos,
- Pablo Tolosa,
- Montserrat Muñoz,
- Blanca González-Farré,
- Patricia Villagrasa,
- Joel S. Parker,
- Charles M. Perou,
- Ana Vivancos
Affiliations
- Aleix Prat
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Fara Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Olga Martínez-Sáez
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Esther Sanfeliu
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Youli Xia
- Reveal Genomics
- Meritxell Bellet
- SOLTI cooperative group
- Patricia Galván
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Débora Martínez
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Tomás Pascual
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Mercedes Marín-Aguilera
- Reveal Genomics
- Anna Rodríguez
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Nuria Chic
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Barbara Adamo
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Laia Paré
- Reveal Genomics
- Maria Vidal
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Mireia Margelí
- Department of Medical Oncology, Institut Catalan of Oncology - Badalona, Hospital Germans Trias i Pujol
- Ester Ballana
- AIDS Research Institute-IrsiCaixa and Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol
- Marina Gómez-Rey
- Cancer Genomics Group, Vall d´Hebron Institute of Oncology (VHIO)
- Mafalda Oliveira
- SOLTI cooperative group
- Eudald Felip
- Department of Medical Oncology, Institut Catalan of Oncology - Badalona, Hospital Germans Trias i Pujol
- Judit Matito
- Cancer Genomics Group, Vall d´Hebron Institute of Oncology (VHIO)
- Rodrigo Sánchez-Bayona
- Department of Medical Oncology, Hospital Universitario 12 de Octubre
- Anna Suñol
- Department of Medical Oncology, Vall d’Hebron University Hospital, Autonomous University of Barcelona
- Cristina Saura
- SOLTI cooperative group
- Eva Ciruelos
- Department of Medical Oncology, Hospital Universitario 12 de Octubre
- Pablo Tolosa
- Department of Medical Oncology, Hospital Universitario 12 de Octubre
- Montserrat Muñoz
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Blanca González-Farré
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Patricia Villagrasa
- Reveal Genomics
- Joel S. Parker
- Department of Genetics, University of North Carolina
- Charles M. Perou
- Department of Genetics, University of North Carolina
- Ana Vivancos
- Cancer Genomics Group, Vall d´Hebron Institute of Oncology (VHIO)
- DOI
- https://doi.org/10.1038/s41467-023-36801-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 16
Abstract
Plasma ctDNA is a promising method to determine patient outcome in multiple cancer types. Here, the authors use shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in patients with metastatic breast cancer.
